VIDEO: Nanoscope Therapeutics shares status update
Click Here to Manage Email Alerts
CHICAGO — In this Healio Video Perspective from Eyecelerator@AAO, Sam Barone, MD, of Nanoscope Therapeutics discusses the mutation-agnostic gene therapy MCO-010.
Barone said the company recently announced that it is preparing a biologics license application for MCO-010 for retinitis pigmentosa and in the process of starting a phase 3 registrational trial in Stargardt disease.
“As an optogenetic therapy, MCO-010 works with a single intravitreal injection to target the bipolar cells to express a light-sensitive opsin protein, thereby turning these cells into de facto photoreceptors and restoring the potential for vision in conditions where there is advanced photoreceptor loss,” Barone said.
Collapse
Healio Interviews
Read more about
Click Here to Manage Email Alerts